Appendix D: Contraceptive Effectiveness Providers should counsel clients about the effectiveness of different contraceptive methods. Method effectiveness is measured as the percentage of women experiencing an unintended pregnancy during the first year of use, and is estimated for both typical and perfect use (Table).

TABLE. Percentage of women experiencing an unintended pregnancy during the first year of typical use* and the first year of perfect use† of contraception and the percentage continuing use at the end of the first year — United States Method % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at 1 year§ Typical use Perfect use No method¶ 85.0 85.0 Spermicides** 28.0 18.0 42.0 Fertility awareness-based methods 24.0 47.0 Standard days method†† 5.0 2-day method†† 4.0 Ovulation method†† 3.0 Symptothermal method 0.4 Withdrawal 22.0 4.0 46.0 Sponge 36.0 Parous women 24.0 20.0 Nulliparous women 12.0 9.0 Condom§§ Female 21.0 5.0 41.0 Male 18.0 2.0 43.0 Diaphragm¶¶ 12.0 6.0 57.0 Combined pill and progestin-only pill 9.0 0.3 67.0 Evra patch 9.0 0.3 67.0 NuvaRing 9.0 0.3 67.0 Depo-Provera 6.0 0.2 56.0 Intrauterine contraceptives ParaGard (copper T) 0.8 0.6 78.0 Mirena (LNG) 0.2 0.2 80.0 Implanon 0.05 0.05 84.0 Female sterilization 0.5 0.5 100.0 Male sterilization 0.15 0.1 100.0

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.



References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.